🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

15 recruiting trials

for EGFR Activating Mutation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965NA1 site📍 Guangzhou Guangzhou University of Traditional Chinese Medicine · Tests: Furmonertinib 320mg qod po, Furmonertinib 160mg qd po CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease NCT05257967NA1 site📍 Vancouver British Columbia Cancer Agency · Tests: Lumbar puncture and Phlebotomy Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites📍 Fullerton📍 Los Angeles📍 Orange ArriVent BioPharma, Inc. · Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor NCT07755397Phase 16 sites📍 Surat📍 Bangalore📍 Mumbai Jubilant Therapeutics India Limited · Tests: JBI-778 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain NCT06741085Phase 28 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: osimertinib, stereotactic radiosurgery (SRS) A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations NCT06706076Phase 1, Phase 242 sites📍 Phoenix📍 Irvine📍 La Jolla BlossomHill Therapeutics · Tests: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643 A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819Phase 254 sites📍 Birmingham📍 Duarte📍 Fort Myers Bayer · Tests: BAY2927088 Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases NCT05768490Phase 31 site📍 Guangdong Sun Yat-sen University · Tests: brain radiotherapy, Almonertinib Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728Phase 32 sites📍 Changsha📍 Shanghai TYK Medicines, Inc · Tests: TY-9591, placebo Osimertinib, Osimertinib, placebo TY-9591 A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) NCT06053099NA36 sites📍 Angers📍 Bayonne📍 Boulogne Intergroupe Francophone de Cancerologie Thoracique · Tests: Plasma ctDNA, FFPE blocks EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC NCT07637448Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: EGFR-TKIs Combined with PD-1 Monoclonal Antibody Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial NCT06363734Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Osimertinib plus Dalpiciclib A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker NCT06156527Phase 25 sites📍 Suwon📍 Goyang-si📍 Suwon National Cancer Center, Korea · Tests: Lazertinib, Bevacizumab Injectable Product
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy